Sinopharm Group Co Ltd
HKEX:1099
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.06
23.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sinopharm Group Co Ltd
Sinopharm Group Co Ltd
Cost of Revenue
Sinopharm Group Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Cost of Revenue
-¥543.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-13%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Cost of Revenue
-¥242.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-12%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Cost of Revenue
-¥137.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-14%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Cost of Revenue
-¥47.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-16%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Cost of Revenue
-¥28.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Cost of Revenue
-¥66.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-12%
|
|
Sinopharm Group Co Ltd
Glance View
Sinopharm Group Co., Ltd. stands as a formidable player in the global healthcare landscape, rooted in its status as China's largest distributor of pharmaceuticals and healthcare products. Established in 1998 and publicly traded since 2003, the company plays a central role in the life sciences sector, producing not only a diverse range of medicines and vaccines but also engaging in extensive logistics and supply chain management that ensures healthcare products reach every corner of the vast Chinese market. This comprehensive approach to healthcare distribution is complemented by its robust R&D initiatives, which are driving innovations across multiple therapeutic areas. Notably, Sinopharm became internationally recognized for its key role in the production and distribution of COVID-19 vaccines, further solidifying its prominence in the industry and widening its investor appeal amid a heightened focus on public health. As an investor, Sinopharm’s strategic positioning in the healthcare ecosystem presents a compelling opportunity for long-term growth. With a strong emphasis on integrating technology within its operations, the company aims to enhance operational efficiencies and improve patient outcomes. Additionally, its ongoing expansion into international markets positions Sinopharm not only to capitalize on China's booming healthcare sector but also to tap into the global demand for high-quality medical products. Backed by a solid financial performance and favorable government policies, investors can view Sinopharm as a potential cornerstone in a diversified portfolio, blending stability with the prospects of future innovation and expansion.
See Also
What is Sinopharm Group Co Ltd's Cost of Revenue?
Cost of Revenue
-543.2B
CNY
Based on the financial report for Jun 30, 2024, Sinopharm Group Co Ltd's Cost of Revenue amounts to -543.2B CNY.
What is Sinopharm Group Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-13%
Over the last year, the Cost of Revenue growth was 0%. The average annual Cost of Revenue growth rates for Sinopharm Group Co Ltd have been -6% over the past three years , -8% over the past five years , and -13% over the past ten years .
You don't have any saved screeners yet
